Characteristic	Respondents
People currently receiving gender‐affirming hormone therapy*	448
Difficulty with access (eg, disrupted pharmacy supply)	153 (34%)
Difficulty obtaining prescriptions	67 (15%)
Difficulty administering hormones (eg, finding somewhere for providing injection)	60 (13%)
Process for commencing hormone therapy delayed	18 (4%)
People with gender‐affirming surgery booked since 1 May 2020	85
Surgery postponed or cancelled	37 (44%)
Surgery proceeded as planned	48 (56%)
People receiving post‐gender‐affirming surgery care since 1 May 2020	96
Disruptions experienced	40 (42%)
No disruptions experienced	53 (55%)
Unsure	12 (3%)
Used telehealth services
Yes	471 (91%)
No	43 (8%)
Unsure	3 (1%)
People who reported telehealth experiences*	470
Telehealth more accessible than in‐person appointments	372 (79%)
Telehealth just as effective or more effective than in‐person appointments	145 (31%)
Telehealth less accessible than in‐person appointments	60 (13%)
Telehealth less effective than in‐person appointments	205 (43.6%)
Unsure	12 (3%)

* Multiple responses possible.